Ajanta Pharma announces the final approval from USFDA and launch of Omeprazole and Sodium Bicarbonate Capsules in the US market, through its wholly owned subsidiary Ajanta Pharma USA Inc. It is a bioequivalent prescription generic version of Zegerid and the company has launched the product in 2 strengths 20mg/1100mg & 40mg/1100mg capsules.
Omeprazole and Sodium Bicarbonate Capsules is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 11 ANDAs; tentative approvals for 1 ANDA; and 14 ANDAs are under review with US FDA.
Ajanta Pharma Ltd is currently trading at Rs. 1626.45, up by Rs. 28.35 or 1.77% from its previous closing of Rs. 1598.1 on the BSE.
The scrip opened at Rs. 1604.8 and has touched a high and low of Rs. 1647 and Rs. 1593.9 respectively. So far 277655(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 14064.08 crore.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1720 on 12-Aug-2015 and a 52 week low of Rs. 1103 on 18-Jan-2016. Last one week high and low of the scrip stood at Rs. 1659 and Rs. 1591.4 respectively.
The promoters holding in the company stood at 73.78 % while Institutions and Non-Institutions held 12.06 % and 14.16 % respectively.
The stock is currently trading above its 50 DMA.